Meet the Team
At TheraCea Pharma, our strength lies in our people - a multidisciplinary team of scientists, clinicians, and innovators dedicated to advancing next-generation radiopharmaceuticals for precision medicine. Our leadership brings decades of combined experience in chemistry, molecular imaging, translational research, nuclear medicine, and clinical oncology, working closely with academic, clinical, and industry partners to accelerate the path from discovery to patient impact.
Together, we unite scientific rigor, entrepreneurial drive, and a shared vision to redefine how targeted imaging and therapy improve outcomes for patients worldwide.
Chief Executive Officer
Dr. Daryaei leads the company’s vision to translate cutting-edge science into impactful healthcare solutions. With a background spanning chemistry, molecular imaging, and translational medicine, he combines entrepreneurial insight and technical expertise to advance novel diagnostics and therapeutics addressing oncology and neurological diseases.
Vice President of Business Development
Dr. De Lille leads strategic partnerships, collaborations, and commercialization initiatives. With over two decades of experience spanning imaging science, diagnostics, and radiopharmaceutical services, she has held key leadership roles driving growth and client engagement at leading CROs and biotech companies.
Chief Medical Officer
Dr. Hurt is a physician-scientist with a distinguished background in radiopharmaceutical development. Before joining TheraCea, he contributed to the clinical advancement of AlphaMedix(²¹²Pb-DOTATATE) at OranoMed. His work bridges clinical strategy, trial execution, and regulatory development.
Vice President of Preclinical R&D
Dr. Rychetsky oversees TheraCea Pharma’s preclinical therapeutic and diagnostic pipeline programs. A pharmaceutical industry veteran with more than 30 years of experience at leading companies such as Sanofi, he brings deep expertise in the preclinical development of therapeutic assets, including peptide-based drugs and biologics.
VP of Regulatory Strategy and Compliance
Dr. Waterhouse leads regulatory planning, quality systems, and compliance operations across the company’s diagnostic and therapeutic programs. With a background spanning regulatory affairs, clinical operations, and quality assurance in both pharmaceutical and biotechnology sectors, she provides strategic oversight to ensure efficient translation of TheraCea’s innovations from research to clinical application.
